Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dismal survival outcomes of patients with acute myeloid leukemia after failure of venetoclax with hypomethylating agents.
Zainaldin C, Arora S, Bathini S, Gupta U, Pandya V, Bae S, Worth S, Bachiashvili K, Bhatia R, Godby K, Jamy O, Rangaraju S, Diamond B, Oliver JD, Salzman D, Di Stasi A, Vachhani P. Zainaldin C, et al. Among authors: worth s. Leuk Lymphoma. 2022 Dec;63(13):3245-3248. doi: 10.1080/10428194.2022.2113530. Epub 2022 Sep 15. Leuk Lymphoma. 2022. PMID: 36107006 No abstract available.
Tumor lysis syndrome and infectious complications during treatment with venetoclax combined with azacitidine or decitabine in patients with acute myeloid leukemia.
Arora S, Zainaldin C, Bathini S, Gupta U, Worth S, Bachiashvili K, Bhatia R, Godby K, Jamy O, Rangaraju S, Diamond B, Oliver JD, Salzman D, Di Stasi A, Vachhani P. Arora S, et al. Among authors: worth s. Leuk Res. 2022 Jun;117:106844. doi: 10.1016/j.leukres.2022.106844. Epub 2022 Apr 25. Leuk Res. 2022. PMID: 35487134
Utility of end of induction bone marrow biopsy and survival outcomes in acute promyelocytic leukemia treated with fixed-dose induction regimen.
Dunn-Valadez S, Bathini S, Purdy KE, Bachiashvili K, Bhatia R, Jamy O, Rangaraju S, Mehta A, Godby K, Goyal G, Worth S, Oliver JD, Mikhail FM, Choi JK, Morlote D, Reddy VB, Vachhani P. Dunn-Valadez S, et al. Among authors: worth s. Leuk Lymphoma. 2023 Oct;64(10):1673-1680. doi: 10.1080/10428194.2023.2234529. Epub 2023 Jul 26. Leuk Lymphoma. 2023. PMID: 37493540
Post-remission cytopenia management in patients with AML treated with venetoclax in combination with hypomethylating agents: Pre- versus post-VIALE-A real-world experience from a predominantly US community setting.
Vachhani P, Ma E, Xu T, Montez M, Worth S, Yellow-Duke A, Cheng WH, Werner ME, Abbas J, Donnellan W. Vachhani P, et al. Among authors: worth s. Cancer Med. 2023 Sep;12(17):17914-17923. doi: 10.1002/cam4.6430. Epub 2023 Aug 11. Cancer Med. 2023. PMID: 37568276 Free PMC article.
Recovery Barrier Characterizations by Hospitalized Patients with Substance Use Disorders: Results from a Randomized Clinical Study on Inpatient Peer Recovery Coaching.
Byrne KA, Roth PJ, Cumby S, Goodwin E, Herbert K, Schmidt WM, Worth S, Connolly K, Uzor O, Eiff B, Black D. Byrne KA, et al. Among authors: worth s. Int J Environ Res Public Health. 2024 Jan 14;21(1):93. doi: 10.3390/ijerph21010093. Int J Environ Res Public Health. 2024. PMID: 38248556 Free PMC article. Clinical Trial.
34 results